Transforming healthcare by unlocking the power of blood flow data.


In 2023, NeuraSignal proudly acquired the business of NovaSignal, yet our origin story traces back a decade earlier. Originally known as NovaSignal, our foundation was laid in 2013 with a single-minded mission: to facilitate greater access to crucial medical data, enabling physicians to profoundly enhance patient care.

The foundational technology behind NeuraSignal was     developed by Co-Founder Dr. Robert Hamilton during his Ph.D. studies in the Department of Neurosurgery at UCLA. Dr. Hamilton's extensive hands-on experience in the neurocritical care unit, coupled with his international research pursuits in countries like Haiti, China, and Malawi, served as the backdrop to our story. In these regions, where medical technological access was often restricted, he witnessed firsthand the need for reliable data to improve patient outcomes.

This profound realization and the subsequent introduction to MBA students Dan Hanchey and Leo Petrossian marked the inception of NeuraSignal. Together, they embarked on a journey of innovation and commitment, which continues to impact lives and redefine medical technology standards across the globe.

NeuraSignal is founded
NeuraSignal receives a $3M grant from the NIH to study traumatic brain injury and stroke

The Lucid™ M1 receives FDA 510(k) clearance
Lucid M1 receives CE Mark approval and NeuraSignal opens its first office in Europe

Awarded $10M grant from the Department of Defense
The NeuralBot™ receives FDA clearance, paving the way for the Lucid™ Robotic System to become the first fully-automated ultrasound.
The first commercial Lucid Robotic System is acquired by Houston Methodist University to monitor blood flow during open heart surgery.
NeuraSignal launches the NovaSignal Platform including the second generation of the NovaGuide Intelligent Ultrasound, and NovaGuide View which provides secure, cloud-based access to dynamic exam data.

Making a difference in communities across the globe

The inspiration behind NeuraSignal traces back to       the country of Malawi in sub Saharan Africa. It was here that co-founder, Robert Hamilton utilized transcranial doppler ultrasound as a tool to research pediatric malaria and sickle cell anemia. The challenges of this resource-constrained environment underscored the need for automation and broader technological access. In line with their commitment to advancing healthcare, NeuraSignal recently donated eight Lucid™ TCD systems to Nationwide Children’s Hospital, supporting the establishment of specialized research centers focused on malaria and sickle cell anemia throughout sub-Saharan Africa .  

Want to learn more? Get in touch.